Thermo Fisher Scientific (BUE:TMO) ROCE % : 10.32% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Thermo Fisher Scientific ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Thermo Fisher Scientific's annualized ROCE % for the quarter that ended in Dec. 2023 was 10.32%.

Thermo Fisher Scientific ROCE % Historical Data

The historical data trend for Thermo Fisher Scientific's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thermo Fisher Scientific ROCE % Chart

Thermo Fisher Scientific Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

11.33

16.03

14.53

13.24

12.59

Thermo Fisher Scientific Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															11.21	9.06	9.70	12.33	10.32

Thermo Fisher Scientific ROCE % Calculation

Thermo Fisher Scientific's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	2769953.002	/	( ( (16287867.649 - 2851726.421)	+	(35640086.032 - 5058332.005) )	/ 2 )
	=	2769953.002	/	( (13436141.228	+	30581754.027)	/ 2 )
	=	2769953.002	/	22008947.6275
	=	12.59 %

Thermo Fisher Scientific's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	3075720.004	/	( ( (33965098.086 - 4954592.236)	+	(35640086.032 - 5058332.005) )	/ 2 )
	=	3075720.004	/	( ( 29010505.85	+	30581754.027 )	/ 2 )
	=	3075720.004	/	29796129.9385
	=	10.32 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Thermo Fisher Scientific (BUE:TMO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Thermo Fisher Scientific ROCE % Related Terms

Thank you for viewing the detailed overview of Thermo Fisher Scientific's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Thermo Fisher Scientific (BUE:TMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thermo Fisher Scientific Inc (BUE:TMO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TMO:USA TMO:Peru TMO:Mexico TN8:Germany TMOS34:Brazil

Address

168 Third Avenue, Waltham, MA, USA, 02451

Website

https://www.thermofisher.com

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%).